Brain Cancer | Specialty

PD1 Inhibitor DNA Vaccine Combination Trial in GBM

March 5th 2018

DNA Vaccine Creating Immunogenicity in GBM

March 5th 2018

Efficacy of Checkpoint Inhibition in Glioblastoma

March 5th 2018

Challenges With Immunotherapy in Glioblastoma

March 5th 2018

Novel Combo Explored for Rare Brain Tumor

March 5th 2018

Investigators are seeking to determine whether the combination of eflornithine with lomustine can improve survival for patients with recurrent anaplastic astrocytoma.

DNX-2401 Demonstrates "Dramatic" Survival Benefit in Glioma

February 15th 2018

Treatment with the investigational agent DNX-2401 resulted in 20% of a cohort of patients with recurrent malignant glioma surviving more than 3 years from the time of treatment.

Tumor-Treating Fields Extend Survival in Glioblastoma

January 19th 2018

Adding tumor-treating fields to temozolomide resulted in improved progression-free survival and overall survival for patients with glioblastoma.

Oncolytic Virus Therapy Passes Early Efficacy Tests in Glioma Subtypes

January 7th 2018

A2-step oncolytic virus has demonstrated promising signals against aggressive forms of brain cancers, including recurrent glioblastoma multiforme and anaplastic astrocytoma, in early clinical studies.

FDA Grants Bevacizumab Full Approval for Glioblastoma

December 6th 2017

The FDA has granted bevacizumab a full approval for the treatment of adult patients with glioblastoma that progressed following prior therapy.

Immunotherapy Combinations Offer Hope in Glioblastoma

October 4th 2017

Immunotherapy has shown promise for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with historically poor prognosis, but experts agree that combination regimens have the greatest potential to achieve durable response.

FDA Approves First Biosimilar for Cancer Treatment

September 14th 2017

The FDA approved the first biosimilar for the treatment of cancer. ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), is indicated for the treatment of colorectal, lung, brain, kidney, and cervical cancers in adult patients.

Glioblastoma Platform Trial Investigating Multiple Drugs in Parallel

September 6th 2017

In an ongoing phase II trial, researchers are investigating several targeted agents for use in the treatment of patients with glioblastoma (GBM).

ODAC Unanimously Supports Bevacizumab Biosimilar ABP-215

July 13th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.

"Trojan Horse" Tested in EGFR-Amplified Glioblastoma

July 6th 2017

Investigators are seeking to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide will improve the survival of patients with newly diagnosed glioblastoma multiforme with EGFR amplification.

Tumor Treating Fields Substantially Improve Survival in GBM

April 3rd 2017

Tumor treating fields reduced the risk of death by 37% and overall survival was extended by a median of 5 months for patients with glioblastoma multiforme, in a landmark analysis of the EF-14 trial.

Dr. Stupp on Final Results for TTFields Added to Chemo in Glioblastoma

April 2nd 2017

Roger Stupp, MD, professor, Neurological Surgery, and associate director, Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields (TTFields) added to standard chemotherapy in newly diagnosed glioblastoma during the AACR Annual Meeting.

Patient-Derived Cancer Stem Cells Offer Diagnostic and Therapeutic Potential in Brain Cancer

March 1st 2017

A brain tumor research group at the UW Carbone Cancer Center focuses on biological studies of patient-derived glioblastoma multiforme (GBM) cancer stem cells, combined with analysis of patient-matched serum-cultured GBM and an annotated GBM tissue microarray, to identify clinically relevant biomarkers.

Metabolic Pathways May Lead Researchers to Novel Therapeutic Targets in Neuro-Oncology

December 26th 2016

In neuro-oncology, newfound interest has sparked investigations into metabolic pathways in tumors with the hope of identifying novel therapeutic targets.

Onartuzumab Shows No Additional Benefit When Combined With Bevacizumab in GBM

December 23rd 2016

The addition of onartuzumab to bevacizumab did not provide any increased clinical benefit in the treatment of patients with recurrent glioblastoma multiforme.

The Future of Glioblastoma

December 21st 2016